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Summary Suppression of the secretion of prolactin, growth hormone and insulin-like growth factor 1 (IGF-1) might be important in the growth
regulation and treatment of breast cancer. Because oestrogens may counteract the anti-tumour effects of such treatment, the combination of
an anti-oestrogen (tamoxifen), a somatostatin analogue (octreotide) and a potent anti-prolactin (CV 205-502) might be attractive. In this
respect, we performed a first exploratory long-term study on the feasibility of combined treatment and possible clear differences in endocrine
and anti-tumour effects during such combined treatment vs standard treatment with tamoxifen alone. Twenty-two post-menopausal patients
with metastatic breast cancer (ER and/or PR positive or unknown) were randomized to receive either 40 mg of tamoxifen per day or the
combination of 40 mg of tamoxifen plus 75 ig of CV 205-502 orally plus 3 x 0.2 mg of octreotide s.c. as first-line endocrine therapy. An
objective response was found in 36% of the patients treated with tamoxifen alone and in 55% of the patients treated with combination therapy.
Median time to progression was 33 weeks for patients treated with tamoxifen and 84 weeks for patients treated with combination therapy, but
the numbers are too small for hard conclusions. There was no difference in overall post-relapse survival between the two treatment arms.
With respect to the endocrine parameters, there was a significant decrease of plasma IGF-1 levels in both treatment arms, whereas during
combined treatment plasma growth hormone tended to decrease and plasma prolactin levels were strongly suppressed; in some patients
insulin and transforming growth factor a (TGF-a) decreased during the triple therapy. Although there was no significant difference in mean
decrease of plasma IGF-1 levels between the two treatment arms, combined treatment resulted in a more uniform suppression of IGF-1.
Therefore, the addition of a somatostatin analogue and an anti-prolactin may potentially enhance the efficacy of anti-oestrogens in the
treatment of breast cancer owing to favourable endocrine and possible direct anti-tumour effects. Large phase IlIl trials using depot
formulations (to increase the feasibility) of somatostatin analogues are warranted to demonstrate the potential extra beneficial anti-tumour
effects of such combination therapy.
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Different steroid hormones, peptide hormones, growth factors and
other trophic substances are involved in the growth regulation of
human breast cancer (Clarke et al, 1992; Klijn et al, 1992).
Oestrogens, especially oestradiol, arethe mostpotentgrowth stimula-
tory hormones of breast cancer. Therefore, endocrine treatment of
metastatic breast cancer usually uses antisteroidal agents such as
tamoxifen, resulting inresponse rates of30-40% (Santen etal, 1990).
Together with oestradiol, insulin-like growth factors (IGF-l and
IGF-2) are the most potent mitogens for breast cancer cells
(Osborne et al, 1990; Clarke et al, 1992; Cullen et al, 1992). The
growth effects of both are mediated predominantly via IGF-1
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receptors, which have been demonstrated in 67-93% of primary
human breast cancers (Pekonen et al, 1988; Peyrat et al, 1988a;
Foekens et al, 1989a; Klijn et al, 1993) at higher density than in
normal or benign breast tissue (Peyrat et al, 1988b). In vivo, pitu-
itary-derived growth hormone (GH) regulates endocrinologically
the secretion of IGF-1 (Kelly et al, 1991; Lamberts et al, 1991),
but possibly also has regulatory effects on local IGF-1 secretion
within (tumour) tissues (Davoren et al, 1986; Schally et al, 1987;
Kelly et al, 1991). In addition, in breast cancer local production of
GH with a potential paracrine function has been described (Mol et
al, 1995). In vitro, physiological concentrations ofthe lactotrophic
hormones GH and prolactin (PRL) can stimulate the growth of
breast cancer cells (Malarkey et al, 1983; Murphy et al, 1984;
Manni et al, 1986; Bonneterre et al, 1990). In primary human
breast cancers, receptors for these lactotrophic hormones have
been demonstrated in 13-72% of series of tumours investigated
depending on the techniques used (Bonneterre et al, 1990).
Furthermore, increased plasma levels ofboth GH (Emerman et al,
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Table 1 Patient characteristics
Tamoxifen Combination Total
therapy
Number of patients entered 12 10 22
Number of patients evaluable 11 9 20
Menopausal status:
Post 10 9 19
Peri 1 0 1
Age
Mean (range) 59 (49-71) 62 (49-73) 60 (49-73)
WHO performance status
0 6 5 11
1 3 2 5
2 2 2 4
Disease sites
Soft tissue 3 3 6
Lymph nodes 1 1 2
Bone 9 6 15
Liver 4 1 5
Lung 2 3 5
Number of disease sites
1 5 5 10
2 5 3 8
3 0 1 1
4 1 0 1
Receptor status (in tumour or metastases):
ER and/or PR positive 10 6 16
ERand PR unknown 1 3 4
1985) and PRL (Holtkamp et al, 1984; Emerman et al, 1985) as
well as of IGF-1 (Peyrat et al, 1993) have been found in patients
with breast cancer. Therefore, suppression ofGH, PRL and IGF-1
secretion might be important in the treatment ofbreast cancer.
Suppression of GH and IGF-1 secretion can be induced by
somatostatin and its analogues (Schally et al, 1987; Schally et al,
1988; Manni et al, 1989, Pollak et al, 1989; Lamberts et al, 1991;
Lamberts et al, 1996). Interestingly, receptors for somatostatin
(SSTR) have also been demonstrated in 36-67% of primary
human breast cancers (Reubi et al, 1990; Fekete et al, 1989; Klijn
et al, 1992; 1993) and in even 75% by in vivo receptor scintig-
raphy (Van Eijck et al, 1994), indicating that somatostatin
analogues can directly affect tumourgrowth. Indeed, we (Setyono-
Han etal, 1987) and others havepreviously shown (Lamberts etal,
1991; Weckbecker et al, 1992) direct growth-inhibitory effects of
somatostatin analogues on human breast cancer cell lines.
Based on the data mentioned above, it can be concluded that
somatostatin analogues and antiprolactins can have beneficial
direct and indirect effects on the treatment of breast cancer.
However, until now a single treatment with these agents showed
only minor activity in post-menopausal patients with metastatic
breast cancer (European Breast Group, 1972; Minton et al, 1974;
Engelsman et al, 1975; Grisoli et al, 1981; Morten et al, 1988;
Manni et al, 1989; Vennin et al, 1989; Holtkamp et al, 1990; Klijn
et al, 1992). Because unopposed oestrogen action can overrule the
growth inhibitory effects of somatostatin analogues (Setyono-Han
et al, 1987) and/or anti-prolactions, combination treatment With
an anti-oestrogen, a somatostatin analogue and an anti-prolactin
might be ofvalue and may increase the efficacy ofsingle treatment
Table 2 Mean plasma levels of hormones and growth factors before and during treatment
Hormone/ Treatment Number of evaluable Pretreatment Absolute change
growth factor patients value from pretreatment
(n) (mean ± s.d.) value (mean ± s.d.)
E2 TAM 7 87 ± 75 - 21 ± 63
(pmol 1-') Combined 6 83± 80 - 17 ± 74
P= 0.48*
nGH TAM 10 0.8 ± 1.2 + 1.23± 1.78
(I') Combined 7 2.6 ± 3.1 - 1.3 ± 3.32
P= 0.10
PRL TAM 10 5.2 ± 1.9 - 0.77± 2.62
(gg I-') Combined 7 8.0 ± 5.2 - 5.5 ± 4.85
P= 0.006
Insulin TAM 10 25.7 ± 15.3 + 15.6 ± 39.8
(mU 1-') Combined 7 57.5 ± 41.4 - 32 ± 37.6
P=0.02
TGF-a TAM 10 0.30 ± 0.14 + 0.02 ± 0.09
(ng ml-') Combined 8 0.39 ± 0.13 - 0.08 ± 0.12
P= 0.11
IGF-1 TAM 10 149±64 -62±47
(ng ml-') Combined 8 137 ± 39 - 69 ± 28
P= 0.63
*P-values indicate differences in decrease between the two treatment groups. TAM, tamoxifen; Combined, combination treatment with tamoxifen, octreotide and
CV 205-502.
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Figure 1 Effect of tamoxifen (left) and of combination treatment (right) on plasma hormone and growth factor concentrations. The zero lines represent the
basal pretreatment values, whereas the absolute individual changes are indicated as determined 4-24 weeks after the start of treatment
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with tamoxifen alone. As tamoxifen affects growth factor secre-
tion (Coletti et al, 1989; Pollak et al, 1990; Clarke et al, 1992;
Kiang et al, 1992; Lonning et al, 1992; Reed et al, 1992; Winston
et al, 1994) such combination treatment might be extra attractive.
However, clinical results of such combined treatment modality
have not yet been reported. In this paper, we report on the
feasibility, the endocrine and long-term anti-tumour effects of
combined treatment with tamoxifen, the somatostatin analogue
octreotide and a new potent dopamine agonist (the anti-prolactin
CV 205-502) in comparison with those of single treatment with
tamoxifen, as well as an in-depth discussion about the mechanisms
ofaction and an elaborate overview ofliterature data.
PATIENTS AND METHODS
The study was performed after approval by a local Human
Investigations Committee (trial DDHK 88-30). Between August
1989 and May 1991, 22 post-menopausal patients with previously
untreated metastatic breast cancer were randomized to be treated
within this trial afterprevious informed consent. Thepatients char-
acteristics are summarized in Table 1. Twopatients were not evalu-
able: one stopped treatment with octreotide within 2 days because
the patient could not tolerate daily injections and another patient
stopped single treatment with tamoxifen within 2 months because
ofthe detection ofan endometrial carcinoma. Later on, one patient
appeared to be perimenopausal because of a rise in oestradiol
levels after the start of treatment with tamoxifen. Therefore, this
patient was not included in the analysis for oestradiol levels.
Currently, the mean follow-up of all 20 evaluable patients is 3
years (range 3 months-6 years). Within this follow-up period all
but two patients showed progressive disease and 14 died.
The patients were randomized to be treated with either tamox-
ifen 40 mg perday or with the combination treatmentconsisting of
40 mg of tamoxifen, 75 ,ug of the dopamine agonist CV 205-
502 (Norprolac) and the somatostatin analogue octreotide
(Sandostatin) 200 mg t.i.d. subcutaneously every day. Dose modi-
fication was not allowed. The duration oftreatment varied from 6
weeks to more than 6 years. Patients were evaluated for toxicity
and response every 6-12 weeks. Measurements of tumour
response were performed according to the UICC criteria.
Plasma samples for measurement ofbasal hormone and growth
factor concentrations (Table 2) were taken before and regularly
between 4-24 weeks after start of treatment (Figure 1). Plasma
peptide hormones and growth factors were measured by radio-
immunoassays and radioreceptor assay (TGF-a), as described
previously (Klijn et al, 1990a). Plasma oestradiol levels were
measured by radioimmunoassay.
Statistical methods
The expected accrual rate per year was 60 patients. Because of a
much lower actual recruitment, in particular because ofthe refusal
of daily injections in the combined treatment arm, the trial was
closed after the inclusion of 22 patients in 2 years. Because ofthe
relatively low number of patients in this study, the analysis of the
data has been primarily descriptive, directed at the calculation of
response rate, progression-free survival with actuarial methods
and a description of the endocrine effects of the treatments by
calculating the change in plasma concentration levels from the
baseline. Because of the limited power of this study to detect
differences between treatment arms, all P-values reported in this
Table 3 Type of responses and time to progression (in weeks)
CR PR SD PD
Tam 1 3 3 4
(162) (32,66,78) (25,39,159) (10-21)
Combination 2 3 2 2
treatment (171,209) (84,86,115) (22,36) (7,11)
paper should be regarded as exploratory. The log-rank test was
used for the comparison of progression free survival. The
Mann-Whitney non-parametric two-sample test was used to
compare the change in plasma levels in both treatment groups.
RESULTS
Endocrine effects of treatment
Figure 1 shows the absolute change from baseline in plasma
hormone and growth factor concentrations for all patients with
evaluable measurements. As no trend was apparent in the values
during treatment from 1 month after the start oftreatment, for each
patient all these values measured between 4 and 24 weeks are
summarized by the mean. Table 2 shows the mean pretreatment
values and the absolute mean change ofeach ofthe endocrine para-
meters from pretreatment values. Pretreatment basal oestradiol
levels were similar in both treatment groups and the values during
treatment did not show a systematic change. Basal GH showed a
small decrease in four out of seven investigated patients during
combined treatment and in none of the ten patients during single
treatment with tamoxifen (Figure 1), but in view of differences in
pretreatment values and a large variation during treatment there was
only a trend for a difference (P = 0.10) between the two treatment
arms (Table 2). Most interesting was the significant decrease
(P < 0.0002) ofplasmaIGF-l levels during treatment (Figure 1), i.e.
overall a mean decrease of 49% during combined treatment and
38% during single treatment with tamoxifen. This decrease showed
no significant difference between the two treatment groups, either
absolutely (P = 0.63, Table 2) and percentually (P = 0.21).
However, IGF-1 suppression was more uniform during combined
treatment in contrast to a strong variation in response during tamox-
ifen treatment (Figure 1). In plasma prolactin levels, the combined
treatment caused aclearly significant suppression ofprolactin secre-
tion owing to the antiprolactin CV 205-502, whereas tamoxifen had
no significant effect (Figure 1, Table 2, P = 0.006).
In the other endocrine parameters, some patients showed a
decrease of plasma insulin and TGF-x levels during combined
treatment (Figure 1), but differences in overall results between
the two treatment arms (Table 2) were only found for insulin
(P = 0.02) and not for TGF-a (P = 0.11).
Anti-tumour effects
Five (55%) out of nine patients treated with the combination
therapy showed an objective response compared with 4 (36%) out
of 11 patients treated with tamoxifen alone (Table 3). The median
time to progression was 84 weeks for the patients treated with
combination therapy vs 32 weeks for patients treated with tamox-
ifen. Progression-free survival was slightly better for patients
treated with the combination of drugs than those treated with
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Figure 2 Actuarial progression-free survival curves for th
groups
tamoxifen alone (Figure 2), but the number ofpatic
bility study are too few to draw definite conclusior
difference between the two treatment arms with r
post-relapse survival.
Toxicity
Treatment with the triple endocrine combination t
to be feasible, but a significant number (about 40-
tially eligible patients refused randomization beca
sion ofthree daily subcutaneous injections with Sa
one of the treatment arms. However, subjective s
minimal in both treatment arms. During comb
shortly after the start of treatment, slight nausea
was observed in a minority of the patients,
complaints were reported. One patient with diabet(
persistent fall in plasma glucose levels during cc
needing the reduction of daily insulin dosages (m
quence of suppression of glucagon secretion by
most important side-effect was the development
gallbladder stones in one patient treated with coml
DISCUSSION
The relative role of PRL, GH and IGF-I in the d
treatment of human breast cancer is not clearly
three peptides have been observed to be increasec
a variable percentage of breast cancer patients (
1984; Emerman et al, 1985; Peyrat et al, 1993).
tion of breast cancer cells by these peptides car
monoclonal antibodies (Pollak et al, 1988; Arte
Ginsburg et al, 1995; Mershon et al, 1995). In a(
peptides (Foekens et al, 1989b; Clarke et al, 19
1993; Ginsburg et al, 1995; Mershon et al, 1995;
and their receptors (Pekonen et al, 1988; Peyr,
Foekens et al, 1989a; Bonneterre et al, 1990; Cl
Klijn et al, 1993), have been demonstrated in al
tumours and/or human primary breast cancers suggesting a role in
autocrine/paracrine cell growth regulation. However, nearly all
endocrine therapies are focused on antagonism of oestradiol, the
primary mitogen for human breast cancer (Santen et al, 1990).
Some trials have tested the value of suppression of prolactin
secretion by dopamine agonists (antiprolactins) (European Breast
Cancer Group et al, 1972; Minton et al, 1974; Engelsman et al,
1975; Grisoli et al, 1981; Fentimen et al, 1988; Morten et al, 1988;
Manni et al, 1989; Holtkamp et al, 1990). Initial trials using single
dopaminergic treatment with L-dopa or bromocriptine showed poor
results (European Breast Cancer Group et al, 1972; Minton et al,
nation treatment 1974; Engelsman et al, 1975; Grisoli et al, 1981). Two studies
investigated combination therapy of bromocriptine with antister- -1 oidal treatment. Dogliotti et al (1987) found that bromocriptine in
36 48 combination with high dose progestins reduced the percentage of
patients with progressive disease, but Bonneterre et al (1988)
observed no additional anti-tumour effect of bromocriptine to
tamoxifen. This might be explained by the facts that progestins can
ie two treatment increase plasma PRL levels (Alexieva-Figusch etal, 1984), whereas
tamoxifen has rather inhibitory effects on PRL secretion (Klijn et al,
1985; Lamberts et al, 1990; Malaab et al, 1992). Other authors
(Manni et al, 1989; Bonneterre et al, 1990; Pollak et al, 1992)
assumed that the lack ofanti-tumour effects by single dopaminergic
treatment may have been due to the presence ofhGH, which is also
ents in this feasi- a lactogen and can bind to lactotrophic receptors (Bonneterre et al,
ns. There was no 1990). However, a few pilot studies using combined treatment with
espect to overall bromocriptine and a GH-lowering drug, such as a somatostatin
analogue, showed no impressive effects in heavily pretreated
patients with metastatic breast cancer (Morten et al, 1988; Manni et
al, 1989; Holtkamp et al, 1990; Klijn et al, 1992).
In view of the accumulating evidence regarding the importance
;herapy appeared of IGFs in the growth regulation of breast cancer (Osborne et al,
-50%) of poten- 1990; Clarke et al, 1992), in the past decade there has been an
use ofthe inclu- increasing interest in the GH/IGF axis, in particular because ofthe
mndostatin within development of potent somatostatin analogues, agents which can
,ide-effects were suppress the function of the GH/IGF axis (Schally et al, 1987;
ination therapy, Schally etal, 1988; Manni etal, 1989; Klijn etal, 1990a; Lamberts
grade 1 (WHO) et al, 1991, 1996). This interest was further increased by the detec-
but no serious tion of SSTRs in breast cancer cell lines and tissues (Setyono-Han
es mellitus had a et al, 1987; Srkalovic et al, 1990; Weckbecker et al, 1992; Prevost
)mbined therapy et al, 1994; Buscail et al, 1995) and in about halfofprimary breast
iaybe as a conse- cancers (Fekete et al, 1989; Reubi et al, 1990; Van Eijck et al,
octreotide). The 1994). Indeed, we (Setyono-Han et al, 1987) and others (Lamberts
of asymptomatic et al, 1991; Weckbecker et al, 1992) have demonstrated direct
bination therapy. growth-inhibitory effects by various somatostatin analogues on
different breast cancer cell lines. Inhibition of cell proliferation
seems to be mediated especially by subtypes SSTR2 and SSTR5
(Buscail et al, 1995; Lamberts et al, 1996). In addition, in some
levelopment and experimental animal models somatostatin analogues were able to
understood. All cause inhibition of mammary tumour growth (Rose et al, 1983;
1 in plasma from Schally et al, 1987, 1988; Szende et al, 1989; Weber et al, 1989;
(Holtkamp et al, Lamberts et al, 1991; Weckbecker et al, 1994; Lamberts et al,
Growth stimula- 1996). However, in four clinical studies (Morten et al, 1988;
n be blocked by Manni et al, 1989; Vennin et al, 1989; Holtkamp et al, 1990), treat-
aga et al, 1989; ment of 38 (heavily) pretreated patients with octreotide caused
ddition, all three only one objective response and five times stable disease (together
92; Fields et al, 16%) (Klijn et al, 1992). In addition, in previously untreated
Mol et al, 1995) patients single first-line treatment with octreotide appeared to be
at et al, 1988a; less effective than common standard treatment modalities, which
arke et al, 1992; resulted in early stopping of this treatment arm in an on-going
nimal mammary randomized trial ofthe Mayo Clinics.
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These disappointing results of single somatostatin analogue
treatment (or in combination with an anti-prolactin) can be
explained by our observation that oestradiol abolished these
growth inhibitory effects (Setyono-Han et al, 1987). Therefore, at
the start of the present clinical study in 1989 our study design
testing these drugs in combination with an anti-oestrogen seems to
be more appropriate. Later on, this approach was supported by the
results of different preclinical studies that showed the additive
biological (Huynh et al, 1994) and anti-tumour effects
(Weckbecker et al, 1994; Bogden et al, 1995) of somatostatin
analogues to endocrine therapy with tamoxifen or by surgical
oophorectomy in hormone sensitive tumours in vivo. Meanwhile,
tamoxifen appeared not only to act by blocking the growth stimu-
latory effects ofoestrogens but also to modify growth factor secre-
tion (Coletti et al, 1989; Pollak et al, 1990; Butta et al, 1992;
Clarke et al, 1992; Kiang etal, 1992; Lonning et al, 1992; Pollak et
al, 1992; Reed et al, 1992; Huynh et al, 1994; Winston et al, 1994;
Kopp et al, 1995; Van Roozendaal et al, 1995) and to suppress the
GH/IGF-I axis (Malaab et al, 1992; Pollak et al, 1992;
Tannenbaum et al, 1992) and prolactin secretion (Klijn et al, 1985;
Lamberts, 1990, Malaab et al, 1992). Tamoxifen and other anti-
oestrogens can decrease plasma IGF-1-levels (Coletti et al, 1989;
Pollak et al, 1990; 1992; Kiang et al, 1992; Lonning et al, 1992;
Reed et al, 1992; Winston et al, 1994), but also can down-regulate
IGF-I-R (Freiss et al, 1990) and can suppress IGF-1-induced
breast cancer cell proliferation (Pratt et al, 1993). Furthermore,
both octreotide (Lamberts et al, 1991) and anti-oestrogens (Loning
et al, 1992; Reed et al, 1992; Pratt et al, 1993; Winston et al, 1994)
affect IGF-binding proteins. Thus, additive endocrine and anti-
tumour effects could be expected from combination therapy with
tamoxifen plus a somatostatin analogue and an anti-prolactin.
In our study, tamoxifen caused an increase rather than a
decrease in basal GH concentrations. In contrast, in several
patients combination treatment tended to decrease basal GH
levels. Previously, Pollak et al (1989) and Manni et al (1989)
showed significant suppression of stimulated GH-levels (which
are less affected by fluctuation than basal plasma GH levels during
the day) by octreotide treatment. In contrast to the basal GH
concentration, IGF-I levels are stable during the day. Strikingly,
we found no additive suppressive effects of tamoxifen and
octreotide on mean plasma IGF-1 concentrations, but combination
treatment caused a more uniform suppression ofIGF-1 (Figure 1).
Both single tamoxifen and combination treatment caused a
decrease of about 40-50%. This might partly be explained by the
observation that tamoxifen already increases the release of
endogenous hypothalamic somatostatin, resulting in blunting of
pituitary GH pulse amplitude (Tannenbaum et al, 1992). However,
this does not exclude that clear additive endocrine effects might be
found in studies using lower dosages of tamoxifen (20 instead of
40 mg day-') or higher dosages of somatostatin analogues than
used in our trial. Recently, Kiang et al (1992) reported an inter-
esting observation indicating that the type ofanti-tumour response
is related to the extent ofIGF-I suppression. In our study, we were
not able to confirm this observation.
In basal plasma insulin and TGF-a concentrations, we found no
impressive differences between the two treatment arms, although
the combination therapy had a suppressive effects in some
patients. Although somatostatin analogues might affect LH secre-
tion in premenopausal patients (Chiodera et al, 1986), in our post-
menopausal patients no significant effects on plasma E2 levels
were observed. This finding confirms the results of the study of
Manni et al (1989) who also found no effect of combined
octreotide/bromocriptine treatment on plasma LH, FSH and E2
levels. Finally, with respect to prolactin secretion (which is partly
influenced by oestrogens) the anti-oestrogen tamoxifen tended
to decrease plasma PRL levels, although not significantly.
Interestingly, the new very potent antidopaminergic drug CV
205-502 used in the treatment ofprolactinomas (Rasmussen et al,
1987) caused a strong significant decrease ofbasal prolactin levels
(with about 70%) in our patients with normal PRL secretion. This
suppression is more pronounced than previously reported for
bromocriptine. However, in contrast to oestradiol, it is currently
unknown to which plasma levels PRL has to be suppressed to
contribute to an (potential) extra anti-tumour effect.
With respect to the performance of our study, the triple
endocrine therapy appeared to be feasible in the presence of only
few non-serious side-effects. However, a significant number
(40-50%) of potentially eligible patients refused participation in
the trial because ofthe need of three daily injections in one of the
treatment arms. This problem will be resolved by the application
of depot preparations of somatostatin analogues that are increas-
ingly available. Furthermore continuous administration ofdrugs is
generally more effective than daily injections as demonstrated for
octreotide (Klijn et al, 1990b; Weckbecker et al, 1994). In ourpilot
study, the patients treated with the combination therapy showed
progressive disease from start of treatment less frequently and a
longer progression-free survival, but the numbers are undoubtedly
too small for definite conclusions and our results have to be
confirmed by other much larger studies.
In conclusion, the results ofdifferent preclinical studies indicate
that the addition of a somatostatin analogue (with or without
combination with an antiprolactin) may enhance the anti-tumour
efficacy ofanti-oestrogens in the treatment ofbreast cancer (Huynh
et al, 1994; Weckbecker et al, 1994; Bogden et al, 1995). Our first
randomized clinical study on triple therapy showed that in principle
such an approach is clinically feasible and caused significant
endocrine effects. A large multicentre randomized study in
metastatic breast cancer, using a depot preparation of octreotide
instead ofdaily injections, is warranted (and on-going) to prove the
presence ofsuch potential extra beneficial anti-tumour effect.
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